Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROS-1 study of NVL-520 in ROS1-positive advanced solid tumors
NL-OMON53810Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zidesamtinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Nuvalent. Started Jul 2022; status: recruiting.
02
Drugs
zidesamtinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON53810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53810.